ArticleFrontiers in psychiatry2025
Phosphatidylethanol levels and their association with withdrawal severity among individuals with severe alcohol use disorder seeking inpatient withdrawal management.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to determine if phosphatidylethanol (PEth) levels are associated with alcohol withdrawal severity among individuals seeking inpatient withdrawal management. Methods: A prospective study enrolled individuals undergoing alcohol withdrawal treatment at a ASAM level 4 inpatient unit. Primary outcome was the association between serum PEth levels with alcohol withdrawal medication requirements in diazepam equivalent (mg). Secondary objectives examined associations between PEth levels, Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scores, drinking history, Alcohol Use Disorders Identification Test (AUDIT), and Prediction of Alcohol Withdrawal Severity Scale (PAWSS) scores. Results: Thirty participants (mean age 48.7 years, SD 11.7; 67.7% white) reported average daily alcohol consumption of 14.2 drinks (SD 11.4, range 1.2-47.6) and percent heavy drinking days of 72% (SD 31.9, range 13.3-100). Nine (29%) reported history of withdrawal seizures and seven (22.6%) reported history of delirium tremens. Admission PEth (PO, ng/mL) levels (mean 934.9, SD 546.6; range 42 - 2000-) did not significantly associate with total medication requirements (r=0.05, p=0.78) or CIWA scores (r=0.09 to -0.14, p>0.05). PEth levels showed no significant correlations with AUDIT (r=0.17, p=0.35) or PAWSS scores (r=0.13, p=0.50). However, significant correlations were found between PEth levels and average drinks per day (r=0.54, p=0.002), as well as with the percentage of heavy drinking days (r=0.54, p=0.002). Discussion and conclusions: Consistent with prior reports, PEth levels appear to correlate with patients' alcohol consumption including heavy drinking, but our results did not find that PEth levels predict alcohol withdrawal severity among heavy drinkers seeking inpatient withdrawal management. Further research is warranted to better understand the utility of PEth testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.